Gi Dynamics Inc (GIDYL) 0.0160 $GIDYL
GI Dynamics, Inc.: Appendix 4C: Quarter ended 30 June 2016
BusinessWire - Thu Jul 28, 12:59PM CDT
GI Dynamics, Inc. (ASX: GID) (the Company), a medical technology company that has developed an innovative device to improve outcomes for patients battling type 2 diabetes and obesity, today released its Appendix 4C -- Quarterly Cash Flow Report for the quarter ending 30 June 2016 (the Quarter).
GI Dynamics Announces Final Efficacy and Safety Results of U.S. ENDO Trial
BusinessWire - Thu Jun 23, 7:00AM CDT
--Statistically and clinically significant efficacy: 7.7% reduction in body weight
GI Dynamics Announces Results of EndoBarrier(R) Therapy Studies at Digestive Disease Week Meeting
BusinessWire - Mon Jun 13, 7:00AM CDT
--EndoBarrier treatment shows reduction in hepatic fat of 81% and 6x liraglutide effect, an initial indication that EndoBarrier may reduce hepatic fat(2)
GI Dynamics Announces EndoBarrier(R) Therapy Data to Be Presented at American Diabetes Association Annual Meeting
BusinessWire - Thu Jun 09, 5:00AM CDT
GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative endoscopically delivered treatment for type 2 diabetes and obesity, announced today that results from three clinical studies involving EndoBarrier Therapy will be presented at the American Diabetes Association's (ADA) 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016.
GI Dynamics Appoints Chief Compliance Officer
BusinessWire - Tue May 10, 5:12AM CDT
GI Dynamics, Inc. (ASX:GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Mr. Brian Callahan to the position of chief compliance officer and executive vice president clinical, regulatory and quality.
GI Dynamics Releases Safety and Efficacy Data for EndoBarrier(R) Therapy
BusinessWire - Mon May 09, 10:15AM CDT
--EndoBarrier plus liraglutide attained 2.1% absolute reduction in HbA1c: 95% attainment of target
GI Dynamics Appoints Chief Financial Officer
BusinessWire - Thu May 05, 3:17PM CDT
GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Jim Murphy to the position of chief financial officer.
GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President & Chief Executive Officer
BusinessWire - Wed Mar 23, 8:54AM CDT
The Board of Directors of GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced the appointment of Scott Schorer as President and CEO, effective immediately. Mr. Schorer brings nearly 20 years of executive experience in the medical device industry, having founded and/or led numerous companies in the healthcare space.
GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier(R) Therapy (the ENDO Trial)
BusinessWire - Tue Mar 15, 5:00AM CDT
GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced it has received the initial top-line results from its U.S. pivotal clinical trial of EndoBarrier Therapy for glycemic improvement in inadequately controlled, obese, type 2 diabetic subjects on oral anti-diabetic agents (the ENDO Trial).
GI Dynamics, Inc.: Appendix 4C Quarterly Report Quarter Ended 30 September 2015
BusinessWire - Fri Oct 30, 8:25AM CDT
GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced its financial results for the quarter ended 30 September 2015 (Quarter). The Appendix 4C, which has been prepared in U.S. dollars under U.S. GAAP, is attached and the results disclosed in the Appendix 4C are unaudited.
German Diabetes Society Releases Statement Regarding GI Dynamics' Termination of U.S. ENDO Trial
BusinessWire - Sun Sep 27, 11:01PM CDT
GI Dynamics, Inc. (ASX: GID), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced that the German Diabetes Society (DDG) has published their scientific statement regarding the termination of the U.S. pivotal study (ENDO Trial). The statement balances background for the termination of the FDA study and the preliminary results with the experiences and data observed in Germany.
GI Dynamics, Inc.: Appendix 4C Quarterly Report Quarter Ended 30 June 2015
BusinessWire - Thu Jul 30, 7:15AM CDT
GI Dynamics, Inc. (ASX:GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced its financial results for the quarter ended 30 June 2015 (Quarter). The Appendix 4C, which has been prepared in U.S. dollars under U.S. GAAP, is attached and the results disclosed in the Appendix 4C are unaudited.
GI Dynamics Concludes ENDO Trial
BusinessWire - Thu Jul 30, 7:00AM CDT
--Conference call at 9:00 a.m. AEST on 31 July 2015 (7:00 p.m. EDT on 30 July 2015)
GI Dynamics Announces Results of First Comparative Study of Gastric Bypass and EndoBarrier(R) Therapy on Diabetes Remission at Digestive Disease Week 2015
BusinessWire - Tue May 19, 9:00AM CDT
GI Dynamics, Inc. (ASX: GID), a medical device company providing innovative treatments for type 2 diabetes and obesity, today announced data showing improvement in glucose metabolism following treatment with EndoBarrier(R) Therapy (duodenal-jejunal bypass liner or DJBL) that comes significantly close to improvement achieved with gastric bypass surgery (RYGB) in obese patients with type 2 diabetes. In a poster titled, 'Improvement in Glucose Metabolism after Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Duodenojejunal Bypass,' Dr. Jurgen Stein, Department of Gastroenterology and Clinical Nutrition, Hospital Sachsenhausen, Frankfurt, Germany, presented these findings at the American Gastroenterological Association's annual Digestive Disease Week (DDW) meeting in Washington, D.C.
GI Dynamics, Inc.: Appendix 4C Quarterly Report Quarter Ended 31 March 2015
BusinessWire - Thu Apr 30, 7:00AM CDT
GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the quarter ended 31 March 2015 (Quarter). The Appendix 4C, which has been prepared in U.S. dollars under U.S. GAAP, is attached and the results disclosed in the Appendix 4C are unaudited.
Leading 100 Global Fastest Growing Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Mar 24, 7:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ncq7z/global_fastest) has announced the addition of the "Global Fastest Growing Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. The outlook for the medical device industry seems bright, with sales expected to still increase despite global economies struggling. The medical device market growth rate is expected to accelerate to 4.4% annually and reach $440 billion by 2018. This newly launched report identifies 100 Fastest Growing medical devices/technology/supplies companies globally and covers various aspects of these 100 companies including news, financial/non-financial information and stock market analysis. That is a growth rate almost 33% faster than the prescription drug market, which is expected to grow at a rate of 2.5% annually. The medical device market includes everything from large imaging systems to tongue depressors. While the pharmaceutical market represents a larger amount of dollars, the device market is responsible for more orders and transactions. The medical devices market is a major contributor to the overall healthcare industry with the pharmaceuticals industry leading the healthcare sector. The rising incidence of various diseases in the areas of Cardiovascular devices (CVD), respiratory, oncology, neurology, and many others have expanded the need for faster and better medical devices for treatment and diagnosis. The study of global top 100, by various attributes, in the medical devices market is important mainly due to continuous technological advancements in the medical devices industry and rising demand for medical devices owing to increasing healthcare issues. Report Highlights: - Global Fastest Growing 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Fastest Growing medical devices/technology/supplies companies with foreign companies - International presence of Global Fastest Growing medical devices/technology/supplies companies - Key R&D activities by Global Fastest Growing medical devices/technology/supplies companies Companies Mentioned (Partial List) - Aethlon Medical Inc. (United States) - Anteo Diagnostics Limited (Australia) - Artventive Medical Group, Inc (United States) - Biodrain Medical Inc (United States) - Cardiovascular Systems, Incorporation (United States) - Electrical Geodesics, Inc. (United States) - GI Dynamics, Inc. (United States) - Inovio Pharmaceuticals Inc (United States) - Neurosynaptic Communications Pvt. Ltd (India) - Oncosil Medical Ltd (Australia) - ReNeuron Group plc (United Kingdom) - Rewalk Robotics Ltd (United States) - Scivision Biotech Inc (Taiwan) - SPO Global Inc (United States) - Suda Ltd (Australia) - West Pharmaceutical Packaging India Pvt Ltd (India) - Windmill Health Technologies Private Limited (India) - Xtremum Solutions Private Limited (India) For more information visit http://www.researchandmarkets.com/research/7n...al_fastest
INO: 8.57 (-0.12), CSII: 22.60 (-0.06), AEMD: 5.39 (-0.21)
GI Dynamics Resumes Shipments of EndoBarrier(R) Product
BusinessWire - Mon Dec 01, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that its Notified Body in the European Union, an organization that has been accredited by Member States to assess whether a product meets the requirements of the EU Medical Device Directive 93/42/EEC, has cleared the Company to resume commercial product shipments. Today's decision by the Notified Body will permit the Company to resume commercial activities in all jurisdictions where it was previously selling EndoBarrier(R).
Global Bariatric Surgery Devices Market 2014-2018: Key Vendors are Allergan, Covidien, Ethicon-Endosurgery and Olympus
M2 - Thu Oct 09, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q5bgbt/global_bariatric) has announced the addition of the "Global Bariatric Surgery Devices Market 2014-2018" report to their offering. Obesity is a medical condition wherein there is an excess accumulation of body fat. According to the World Health Organization (WHO), person having body mass index (BMI) of 30 or more is generally considered as obese. It has been characterized as an epidemic. Obesity in children and adults is associated with serious health risks that include hypertension, dyslipidemia, diabetes, fatty liver disease, obstructive sleep apnea, and psychosocial complications. Bariatric surgery is the treatment procedure used to treat obesity. Bariatric surgery devices used are different depending on the type of bariatric procedure being performed. The analysts forecast the Global Bariatric Surgery Devices market to grow at a CAGR of 8.21 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Bariatric Surgery Devices market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sale of bariatric surgery devices. The report, the Global Bariatric Surgery Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Procedure 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Allergan - Covidien - Ethicon-Endosurgery - Olympus - Agency of Medical Innovations - Applied Medical Resources - EndoGastric Solutions - GI Dynamics - Intuitive Surgical - Medtronic - PARE Surgical - Peters-Surgical SAS - ReShape Medical - Spartz FGIA - Surgical IOC - TransEnterix For more information visit http://www.researchandmarkets.com/research/q5..._bariatric
ISRG: 687.67 (+2.05), AGN: 253.14 (+0.21), MDT: 87.04 (-0.04)
GI Dynamics, Inc.: Appendix 4C: Quarter ended 30 June 2016
BusinessWire - Thu Jul 28, 12:59PM CDT
GI Dynamics, Inc. (ASX: GID) (the Company), a medical technology company that has developed an innovative device to improve outcomes for patients battling type 2 diabetes and obesity, today released its Appendix 4C -- Quarterly Cash Flow Report for the quarter ending 30 June 2016 (the Quarter).
GI Dynamics Announces Final Efficacy and Safety Results of U.S. ENDO Trial
BusinessWire - Thu Jun 23, 7:00AM CDT
--Statistically and clinically significant efficacy: 7.7% reduction in body weight
GI Dynamics Announces Results of EndoBarrier(R) Therapy Studies at Digestive Disease Week Meeting
BusinessWire - Mon Jun 13, 7:00AM CDT
--EndoBarrier treatment shows reduction in hepatic fat of 81% and 6x liraglutide effect, an initial indication that EndoBarrier may reduce hepatic fat(2)
GI Dynamics Announces EndoBarrier(R) Therapy Data to Be Presented at American Diabetes Association Annual Meeting
BusinessWire - Thu Jun 09, 5:00AM CDT
GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative endoscopically delivered treatment for type 2 diabetes and obesity, announced today that results from three clinical studies involving EndoBarrier Therapy will be presented at the American Diabetes Association's (ADA) 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016.
GI Dynamics Appoints Chief Compliance Officer
BusinessWire - Tue May 10, 5:12AM CDT
GI Dynamics, Inc. (ASX:GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Mr. Brian Callahan to the position of chief compliance officer and executive vice president clinical, regulatory and quality.
GI Dynamics Releases Safety and Efficacy Data for EndoBarrier(R) Therapy
BusinessWire - Mon May 09, 10:15AM CDT
--EndoBarrier plus liraglutide attained 2.1% absolute reduction in HbA1c: 95% attainment of target
GI Dynamics Appoints Chief Financial Officer
BusinessWire - Thu May 05, 3:17PM CDT
GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Jim Murphy to the position of chief financial officer.
GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President & Chief Executive Officer
BusinessWire - Wed Mar 23, 8:54AM CDT
The Board of Directors of GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced the appointment of Scott Schorer as President and CEO, effective immediately. Mr. Schorer brings nearly 20 years of executive experience in the medical device industry, having founded and/or led numerous companies in the healthcare space.
GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier(R) Therapy (the ENDO Trial)
BusinessWire - Tue Mar 15, 5:00AM CDT
GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced it has received the initial top-line results from its U.S. pivotal clinical trial of EndoBarrier Therapy for glycemic improvement in inadequately controlled, obese, type 2 diabetic subjects on oral anti-diabetic agents (the ENDO Trial).
GI Dynamics, Inc.: Appendix 4C Quarterly Report Quarter Ended 30 September 2015
BusinessWire - Fri Oct 30, 8:25AM CDT
GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced its financial results for the quarter ended 30 September 2015 (Quarter). The Appendix 4C, which has been prepared in U.S. dollars under U.S. GAAP, is attached and the results disclosed in the Appendix 4C are unaudited.
German Diabetes Society Releases Statement Regarding GI Dynamics' Termination of U.S. ENDO Trial
BusinessWire - Sun Sep 27, 11:01PM CDT
GI Dynamics, Inc. (ASX: GID), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced that the German Diabetes Society (DDG) has published their scientific statement regarding the termination of the U.S. pivotal study (ENDO Trial). The statement balances background for the termination of the FDA study and the preliminary results with the experiences and data observed in Germany.
GI Dynamics, Inc.: Appendix 4C Quarterly Report Quarter Ended 30 June 2015
BusinessWire - Thu Jul 30, 7:15AM CDT
GI Dynamics, Inc. (ASX:GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced its financial results for the quarter ended 30 June 2015 (Quarter). The Appendix 4C, which has been prepared in U.S. dollars under U.S. GAAP, is attached and the results disclosed in the Appendix 4C are unaudited.
GI Dynamics Concludes ENDO Trial
BusinessWire - Thu Jul 30, 7:00AM CDT
--Conference call at 9:00 a.m. AEST on 31 July 2015 (7:00 p.m. EDT on 30 July 2015)
GI Dynamics Announces Results of First Comparative Study of Gastric Bypass and EndoBarrier(R) Therapy on Diabetes Remission at Digestive Disease Week 2015
BusinessWire - Tue May 19, 9:00AM CDT
GI Dynamics, Inc. (ASX: GID), a medical device company providing innovative treatments for type 2 diabetes and obesity, today announced data showing improvement in glucose metabolism following treatment with EndoBarrier(R) Therapy (duodenal-jejunal bypass liner or DJBL) that comes significantly close to improvement achieved with gastric bypass surgery (RYGB) in obese patients with type 2 diabetes. In a poster titled, 'Improvement in Glucose Metabolism after Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Duodenojejunal Bypass,' Dr. Jurgen Stein, Department of Gastroenterology and Clinical Nutrition, Hospital Sachsenhausen, Frankfurt, Germany, presented these findings at the American Gastroenterological Association's annual Digestive Disease Week (DDW) meeting in Washington, D.C.
GI Dynamics, Inc.: Appendix 4C Quarterly Report Quarter Ended 31 March 2015
BusinessWire - Thu Apr 30, 7:00AM CDT
GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the quarter ended 31 March 2015 (Quarter). The Appendix 4C, which has been prepared in U.S. dollars under U.S. GAAP, is attached and the results disclosed in the Appendix 4C are unaudited.
Leading 100 Global Fastest Growing Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Mar 24, 7:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ncq7z/global_fastest) has announced the addition of the "Global Fastest Growing Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. The outlook for the medical device industry seems bright, with sales expected to still increase despite global economies struggling. The medical device market growth rate is expected to accelerate to 4.4% annually and reach $440 billion by 2018. This newly launched report identifies 100 Fastest Growing medical devices/technology/supplies companies globally and covers various aspects of these 100 companies including news, financial/non-financial information and stock market analysis. That is a growth rate almost 33% faster than the prescription drug market, which is expected to grow at a rate of 2.5% annually. The medical device market includes everything from large imaging systems to tongue depressors. While the pharmaceutical market represents a larger amount of dollars, the device market is responsible for more orders and transactions. The medical devices market is a major contributor to the overall healthcare industry with the pharmaceuticals industry leading the healthcare sector. The rising incidence of various diseases in the areas of Cardiovascular devices (CVD), respiratory, oncology, neurology, and many others have expanded the need for faster and better medical devices for treatment and diagnosis. The study of global top 100, by various attributes, in the medical devices market is important mainly due to continuous technological advancements in the medical devices industry and rising demand for medical devices owing to increasing healthcare issues. Report Highlights: - Global Fastest Growing 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Fastest Growing medical devices/technology/supplies companies with foreign companies - International presence of Global Fastest Growing medical devices/technology/supplies companies - Key R&D activities by Global Fastest Growing medical devices/technology/supplies companies Companies Mentioned (Partial List) - Aethlon Medical Inc. (United States) - Anteo Diagnostics Limited (Australia) - Artventive Medical Group, Inc (United States) - Biodrain Medical Inc (United States) - Cardiovascular Systems, Incorporation (United States) - Electrical Geodesics, Inc. (United States) - GI Dynamics, Inc. (United States) - Inovio Pharmaceuticals Inc (United States) - Neurosynaptic Communications Pvt. Ltd (India) - Oncosil Medical Ltd (Australia) - ReNeuron Group plc (United Kingdom) - Rewalk Robotics Ltd (United States) - Scivision Biotech Inc (Taiwan) - SPO Global Inc (United States) - Suda Ltd (Australia) - West Pharmaceutical Packaging India Pvt Ltd (India) - Windmill Health Technologies Private Limited (India) - Xtremum Solutions Private Limited (India) For more information visit http://www.researchandmarkets.com/research/7n...al_fastest
INO: 8.57 (-0.12), CSII: 22.60 (-0.06), AEMD: 5.39 (-0.21)
GI Dynamics Resumes Shipments of EndoBarrier(R) Product
BusinessWire - Mon Dec 01, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that its Notified Body in the European Union, an organization that has been accredited by Member States to assess whether a product meets the requirements of the EU Medical Device Directive 93/42/EEC, has cleared the Company to resume commercial product shipments. Today's decision by the Notified Body will permit the Company to resume commercial activities in all jurisdictions where it was previously selling EndoBarrier(R).
Global Bariatric Surgery Devices Market 2014-2018: Key Vendors are Allergan, Covidien, Ethicon-Endosurgery and Olympus
M2 - Thu Oct 09, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q5bgbt/global_bariatric) has announced the addition of the "Global Bariatric Surgery Devices Market 2014-2018" report to their offering. Obesity is a medical condition wherein there is an excess accumulation of body fat. According to the World Health Organization (WHO), person having body mass index (BMI) of 30 or more is generally considered as obese. It has been characterized as an epidemic. Obesity in children and adults is associated with serious health risks that include hypertension, dyslipidemia, diabetes, fatty liver disease, obstructive sleep apnea, and psychosocial complications. Bariatric surgery is the treatment procedure used to treat obesity. Bariatric surgery devices used are different depending on the type of bariatric procedure being performed. The analysts forecast the Global Bariatric Surgery Devices market to grow at a CAGR of 8.21 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Bariatric Surgery Devices market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sale of bariatric surgery devices. The report, the Global Bariatric Surgery Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Procedure 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Allergan - Covidien - Ethicon-Endosurgery - Olympus - Agency of Medical Innovations - Applied Medical Resources - EndoGastric Solutions - GI Dynamics - Intuitive Surgical - Medtronic - PARE Surgical - Peters-Surgical SAS - ReShape Medical - Spartz FGIA - Surgical IOC - TransEnterix For more information visit http://www.researchandmarkets.com/research/q5..._bariatric
ISRG: 687.67 (+2.05), AGN: 253.14 (+0.21), MDT: 87.04 (-0.04)
